Exclusive Summary

• It is a first-line, second-generation antipsychotic listed in the WHO Essential Medicines List, guaranteeing robust and consistent global rigid demand.
• The originator's patent (Risperdal) has long expired, offering a fully mature market with zero patent infringement risk for rapid generic substitution.
• The 1mg dosage is the optimal specification for initial dose titration and precise adjustments, especially for pediatric and elderly patients.
• Driven by the API-to-formulation integration and economics of scale in China, it offers overwhelming cost competitiveness for national tenders and bulk procurement.
• Equipped with internationally standardized CTD dossiers and proven bioequivalence (BE), supporting distributors to achieve swift local regulatory approvals.